797 related articles for article (PubMed ID: 22198291)
1. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
2. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of powders for inhalation: the effect of drug concentration on particle detachment.
Le VN; Hoang Thi TH; Robins E; Flament MP
Int J Pharm; 2012 Mar; 424(1-2):44-9. PubMed ID: 22207163
[TBL] [Abstract][Full Text] [Related]
4. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
5. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Shalash AO; Molokhia AM; Elsayed MM
Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
[TBL] [Abstract][Full Text] [Related]
6. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
7. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
[TBL] [Abstract][Full Text] [Related]
8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
9. Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
Ramachandran V; Murnane D; Hammond RB; Pickering J; Roberts KJ; Soufian M; Forbes B; Jaffari S; Martin GP; Collins E; Pencheva K
Mol Pharm; 2015 Jan; 12(1):18-33. PubMed ID: 25380027
[TBL] [Abstract][Full Text] [Related]
10. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
Le VN; Hoang Thi TH; Robins E; Flament MP
AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
[TBL] [Abstract][Full Text] [Related]
12. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
Shalash AO; Khalafallah NM; Molokhia AM; Elsayed MMA
AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
[TBL] [Abstract][Full Text] [Related]
13. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
Shalash AO; Elsayed MMA
AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
[TBL] [Abstract][Full Text] [Related]
14. Mixing time effects on the dispersion performance of adhesive mixtures for inhalation.
Grasmeijer F; Hagedoorn P; Frijlink HW; de Boer HA
PLoS One; 2013; 8(7):e69263. PubMed ID: 23844256
[TBL] [Abstract][Full Text] [Related]
15. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
Young PM; Wood O; Ooi J; Traini D
Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
[TBL] [Abstract][Full Text] [Related]
16. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
18. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
19. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R
Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553
[TBL] [Abstract][Full Text] [Related]
20. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
